11.73
Precedente Chiudi:
$11.80
Aprire:
$11.72
Volume 24 ore:
287.77K
Relative Volume:
0.26
Capitalizzazione di mercato:
$999.68M
Reddito:
-
Utile/perdita netta:
$-119.87M
Rapporto P/E:
-6.4807
EPS:
-1.81
Flusso di cassa netto:
$-109.90M
1 W Prestazione:
+5.30%
1M Prestazione:
+11.82%
6M Prestazione:
+13.55%
1 anno Prestazione:
+8.81%
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Nome
Oric Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 388-5600
Indirizzo
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Confronta ORIC con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ORIC
Oric Pharmaceuticals Inc
|
11.73 | 950.19M | 0 | -119.87M | -109.90M | -1.81 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
2024-10-31 | Iniziato | Wells Fargo | Overweight |
2024-09-06 | Iniziato | Stifel | Buy |
2024-02-23 | Iniziato | Cantor Fitzgerald | Overweight |
2023-09-22 | Iniziato | Wedbush | Outperform |
2023-03-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2023-03-21 | Aggiornamento | Guggenheim | Neutral → Buy |
2023-03-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
2022-07-18 | Ripresa | Oppenheimer | Perform |
2022-04-04 | Aggiornamento | Citigroup | Neutral → Buy |
2022-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
2022-03-22 | Downgrade | Citigroup | Buy → Neutral |
2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
2022-03-22 | Downgrade | Oppenheimer | Outperform → Perform |
2021-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
2020-08-13 | Iniziato | Robert W. Baird | Outperform |
2020-08-06 | Aggiornamento | Citigroup | Neutral → Buy |
2020-08-03 | Iniziato | H.C. Wainwright | Buy |
2020-05-19 | Iniziato | Citigroup | Neutral |
2020-05-19 | Iniziato | Guggenheim | Buy |
2020-05-19 | Iniziato | JP Morgan | Overweight |
2020-05-19 | Iniziato | Jefferies | Buy |
Mostra tutto
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
What analysts say about ORIC Pharmaceuticals Inc. stockSignificant capital appreciation - Autocar Professional
ORIC Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding risk-reward balance - Autocar Professional
Can ORIC Pharmaceuticals Inc. stock recover from recent declineFree Technical Analysis Support - jammulinksnews.com
Arizona State Retirement System Invests $56,000 in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
What drives ORIC Pharmaceuticals Inc. stock priceExtraordinary performance - Autocar Professional
Is ORIC Pharmaceuticals Inc. a good long term investmentFree Trading Psychology Coaching - jammulinksnews.com
How high can ORIC Pharmaceuticals Inc. stock price go in 2025Massive Gain Ideas - Newser
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Why ORIC Pharmaceuticals Inc. stock attracts strong analyst attentionFree Capital Allocation Plans - Newser
What makes ORIC Pharmaceuticals Inc. stock price move sharplySmart High Yield Swing Trades - Newser
How ORIC Pharmaceuticals Inc. stock performs during market volatilityTop Growth Low Risk Stocks - Newser
Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy? - Yahoo Finance
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 4.9%Should You Sell? - MarketBeat
Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Oric Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated by Analysts at LADENBURG THALM/SH SH - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Research Coverage Started at LADENBURG THALM/SH SH - Defense World
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $19.17 Consensus Price Target from Analysts - MarketBeat
ORIC: New Coverage Initiated with a Buy Rating and $15 Price Tar - GuruFocus
Ladenburg Thalmann initiates ORIC Pharmaceuticals stock with Buy rating By Investing.com - Investing.com UK
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 10% HigherWhat's Next? - MarketBeat
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Oric Pharmaceuticals Inc Azioni (ORIC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):